This was the stock's third consecutive day of losses.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today the dosing of the first subject in the ...

Corbus Pharmaceuticals (CRBP) announced the dosing of the first subject in the single ascending dose / multiple ascending dose portion of the ...

Shares of Corbus Pharmaceuticals Holdings Inc. CRBP rose 2.35% to $6.10 Tuesday, on what proved to be an all-around positive ...

Investment analysts at Lifesci Capital boosted their Q1 2025 earnings per share estimates for shares of Corbus Pharmaceuticals in a research note issued on Tuesday, March 11th. Lifesci Capital analyst ...

Explore the detailed Corbus Pharmaceuticals Holding balance sheet to understand the company’s financial health and stability. This page provides a clear breakdown of key metrics, including total ...

GAITHERSBURG, Md., March 13, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company ...

Corbus Pharmaceuticals (CRBP) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates ...

— We have everything you need: full data on over 700 000 bonds, stocks & ETFs; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; ...

March 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, today provided a ...